SMMT vs. TAK, ARGX, BNTX, TEVA, BGNE, GMAB, VTRS, ITCI, MRNA, and RDY
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Moderna (MRNA), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.
Summit Therapeutics vs.
Summit Therapeutics (NASDAQ:SMMT) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability.
4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Summit Therapeutics had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for Summit Therapeutics and 2 mentions for Takeda Pharmaceutical. Summit Therapeutics' average media sentiment score of 0.65 beat Takeda Pharmaceutical's score of 0.58 indicating that Summit Therapeutics is being referred to more favorably in the media.
Takeda Pharmaceutical has a net margin of 6.49% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 10.00% beat Summit Therapeutics' return on equity.
Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summit Therapeutics has a beta of -0.87, indicating that its stock price is 187% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.
Summit Therapeutics received 203 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 58.38% of users gave Summit Therapeutics an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Summit Therapeutics presently has a consensus price target of $33.57, suggesting a potential upside of 42.74%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.
Summary
Summit Therapeutics and Takeda Pharmaceutical tied by winning 9 of the 18 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SMMT) was last updated on 1/22/2025 by MarketBeat.com Staff
Free SMMT Stock Alerts